# OnCo record nct03040973 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03040973/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03040973", "NCT03040973" ;
  schema:name "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone"@en ;
  schema:description "A phase 2 trial of Capmatinib, Gefitinib and Osimertinib in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03040973/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03040973> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2017-07-04" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/novartis/> .